clinical trial · NCT03619902
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
Generalized Pustular PsoriasisImsidolimab
brief summary
The main objectives of this study are to evaluate the efficacy, safety and tolerability of imsidolimab in adults with active GPP.
started
Jan 30, 2019
primary completion
Jan 20, 2021
completion
Jan 20, 2021
last updated
Sep 16, 2025
detailed description
Single arm, multiple-dose study evaluating the use of imsidolimab for the treatment of GPP.
official title
A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol